Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy

AIDS Research and Human Retroviruses

Volumn 15, Issue 3, 1999, Pages 247-253

  Leigh Brown, Andrew J ^a   Korber, Bette T ^b   Condra, Jon H ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; INDINAVIR; PROTEINASE; PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MUTATION; PHYLOGENY; TIME FACTORS; VARIATION (GENETICS);

EID: 0008896367     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311420     Document Type: Article

References (29)

1. Condra JH, Holder DJ, Schleif WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70:8270-8276.
2. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996;2:760-766.
3. Partaledis JA, Yamaguchi K, Tisdale M, et al.: In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995;69:5228-5235.
4. Patick AK, Rose R, Greytok J, et al.: Characterization of human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol 1995;69:2148-2152.
5. King RW, Garber S, Winslow DL, et al.: Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors. Antiviral Chem Chemother 1995;6:80-88.
6. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, and Blair ED: Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995;39: 1704-1710.
7. Kaplan AH, Michael SF, Wehbie RS, et al.: Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci USA 1994;91:5597-5601.
8. Otto MJ, Garber S, Winslow DL, et al.: In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HTV type 1 protease. Proc Natl Acad Sci USA 1993;90:7543-7547.
9. Markowitz M, Mo H, Kempf DJ, et al.: Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995;69:701-706.
10. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London) 1995;374:569-571.
11. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333:1662-1669.
12. Ingrand D, Weber J, Boucher CAB, et al.: Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: Sustained reduction in viral markers. AIDS 1995;9:1323-1329.
13. Balzarini J, Karlsson A, Perez-Perez MJ, Camarasa MJ, Tarpley WG, and De Clercq E: Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single drug therapy. J Virol 1993;67:5353-5359.
14. Schuurman R, Nijhuis M, van Leeuwen R, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-1419.
15. Richman DD, Havlir D, Corbeil J, et al.: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-1666.
16. Kellam P, Boucher CA, Tijnagel JM, and Larder BA: Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994;75:341-351.
17. Richman DD, Grimes JM, and Lagakos SW: Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1990;3:743-746.
18. Lech W, Wang G, Yang YL, et al.: In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996;70:2038-2043.
19. Kozal MJ, Shah N, Shen N, et al.: Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med 1996;2:753-759.
20. Rose RE, Gong YF, Greytok JA, et al.: Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA 1996;93:1648-1653.
21. Felsenstein J: PHYLIP - phylogeny inference package (version 3.2). Cladistics 1989;5:164-166.
22. Kumar S, Tamura K, and Nei M: MEGA: Molecular Evolutionary Genetics Analysis, version 1.01. Pennsylvania State University, University Park, Philadelphia, 1993.
23. Korber BT, Farber RM, Wolpert DH, and Lapedes AS: Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: An information theoretic analysis. Proc Natl Acad Sci USA 1993;90:7176-7180.
24. 23a. Hosur MV, Bhat TN, Kempf DJ, et al.: Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of HTV protease. J Am Chem Soc 1994;116:847-855.
25. Rose RB, Craik CS, and Stroud RM: Domain flexibility in retroviral proteases: Structural implications for drug resistant mutations. Biochemistry 1998;37:2607-2621.
26. Leigh Brown AJ: Analysis of HIV-1 env gene sequences reveals evidence for a low effective population number in the virus population. Proc Natl Acad Sci USA 1997;94:1862-1865.
27. Leigh Brown AJ and Richman DD: HIV-1: Gambling on the evolution of drug resistance? Nature Med 1997;3:268-271.
28. Frost SDW and Leigh Brown AJ: The genetic structure of HIV-1 populations within patients and the frequency of drug-resistant mutants. In preparation.
29. Maeda Y, Venzon DJ, and Mitsuya H: Altered drug sensitivity, fitness and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 1998;177:1207-1213.